Skip Navigation

Faculty Profiles

Vinod Thourani

Vinod H. Thourani, MD

(Primary Appoitnment) Professor of Surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine

(Secondary Appointment) Professor of Medicine, Department of Medicine, Emory University SOM

Co-Director, Structural Heart and Valve Center of the Emory Heart and Vascular Center, Emory Healthcare

Chief of Cardiothoracic Surgery, Emory University Hospital Midtown

Surgical Director, Transcatheter Aortic Valve Replacement Fellowship, Division of Cardiothoracic Surgery, Department of Surgery, Emory University SOM

Telephone

404.686.2513

Email

vthoura@emory.edu

Certification

American Board of Surgery, American Board of Thoracic Surgery

Year Joined Emory as a Faculty Member

2005

Bio-Summary

Dr. Thourani is a highly productive cardiothoracic surgeon-researcher whose primary focus is developing and refining innovative strategies and devices in the field of structural heart disease and valve surgery. His clinical and research work in transcatheter aortic valve replacement (TAVR) and minimally invasive valvular surgery for high-risk patients with severe aortic stenosis has been particularly significant.

TAVR allows physicians to access and replace a failing aortic valve in a patient's heart through a catheter inserted through a small incision in the thigh or in the side of the chest. The catheter delivers a fully collapsible replacement valve to the diseased valve site during the minimally invasive procedure.

Dr. Thourani was a co-principal investigator of the Emory-based site of the multi-center PARTNER I trial that measured TAVR against traditional open heart surgery, the initial results of which were so promising that the FDA approved the SAPIEN valve used in TAVR in November 2011 for the treatment of patients with aortic stenosis considered too frail for traditional surgery. The valve was approved for use in a wider group of high risk patients in 2012, and later expanded to include patients at intermediate risk in 2016.

Throughout these years up to the present, Dr. Thourani has been a primary investigator in the PARTNER trials, has worked with his team to bring the TAVR option to critically ill patients in Georgia and throughout the region, published numerous studies in major health journals, and amassed the largest body of experience in the Southeast and in the top five TAVR research sites in the U.S.

Dr. Thourani's publications in Dr. Thourani's publications in PubMed

Affiliations

Medical School

Postgraduate Training

Honors and Awards

Current Organizational Memberships

Editorial Boards

Clinical Interests

Research Interests

««return to top